Japan Executives Warn Weak Yen and Currency Volatility Threaten Economy 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
ADNOC Gas Targets Up to $4B Profit in 2026 
South Korean Won Leads Asian FX Losses as Dollar Rises 
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
US Judge Dismisses Gautam Adani Criminal Charges 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Airbus Joins Air India A320 Altitude Drop Probe 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Hyundai Pharmaceutical revealed on Tuesday, July 6, that it has submitted an application so it can start selling its abortion pill in South Korea. The company filed for authorization to market at the Ministry of Food and Drug Safety.
Hyundai Pharm is intending to start selling its Mifegymiso that is composed of four tablets of misoprostol and one tablet of mifepristone. Mifepristone is being sold in Korea under the brand name Mifegyne.
First legal abortion pill in S. Korea
According to The Korea Herald, if the ministry will give a go signal for the sale of Mifegymiso, it would effectively become the very first abortion pill that will be legally marketed in the country. In 2019, the Constitutional Court reversed the ban on abortion in the first 14 weeks of pregnancy, so this paved the way for the pills to be produced.
Hyundai Pharm will be distributing Mifegymiso to the market as a prescription drug. This means that only patients with proper medical advice from health professionals will be able to obtain the drug. Without the supervision of a certified health advisor, an individual will not be allowed to purchase the abortion pill.
The U.S. Food and Drug Administration stated that abortion pills are safe to use in the first nine or 10 weeks of pregnancy. While it seems that more and more groups are supporting and even promoting abortion pills, it was reported that the National Assembly is working on revising the Pharmaceutical Affairs Act so it can bar the advertising of the drug.
The marketing license for Mifegymiso
Korea Biomedical Review reported that Hyundai Pharm’s filing for approval for the abortion drug has gained attention because the Ministry of Health and Welfare already granted repayment for doctor’s education and counseling sessions about medical abortion.
The policy asks doctors to give educational counseling to pregnant women regarding abortion. They are allowed to explain the procedures for abortion, including precautions before and after the surgery. The physicians will also be taught about the physical and mental complications of abortion and contraception.
Meanwhile, Hyundai Pharm stated it will do its best to gain approval. “We will closely work with the drug developer to accelerate the regulatory nod for the drug,” a company official said.
